tenofovir has been researched along with Amazon Black Fever in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, T; Nguyen, MH | 1 |
| Beck, A; Fichtl, A; Seufferlein, T; Zizer, E | 1 |
| Li, RH; Yuan, BH; Zhu, YK | 1 |
| Wong, GL; Yip, TC | 1 |
| Goyal, A; Romero-Severson, EO | 1 |
| Vaillant, A | 1 |
| Akarca, US; Caruntu, FA; Celen, MK; Cornberg, M; Curescu, MG; Dienes, HP; Erhardt, A; Gürel, S; Hardtke, S; Heidrich, B; Idilman, R; Keskin, O; Koch, A; Lüth, S; Manns, MP; Mederacke, I; Papatheodoridis, GV; Port, K; Radu, M; Stift, J; von der Leyen, H; Weber, K; Wedemeyer, H; Wittkop, U; Yalcin, K; Yurdaydin, C; Zeuzem, S | 1 |
| Bertoletti, A; Borghi, M; Ceriotti, F; Ferenci, P; Giovanelli, S; Greco, L; Holzmann, H; Lampertico, P; Loglio, A; Lunghi, G; Perbellini, R; Porretti, L; Prati, D; Tham, CYL; Trombetta, E; Uceda Renteria, SC; van Bömmel, F | 1 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yan, X | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| James, G; Raza, M; Sidhu, P | 1 |
| Béguelin, C; Moradpour, D; Rauch, A; Sahli, R; Suter, F; Vazquez, M; Wandeler, G | 1 |
| Atkinson, A; Battegay, M; Béguelin, C; Bernasconi, E; Calmy, A; Cavassini, M; Friolet, N; Günthard, HF; Lüthi, A; Moradpour, D; Rauch, A; Sahli, R; Schmid, P; Suter-Riniker, F; Wandeler, G | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E | 1 |
| Lee, WM; Tujios, SR | 1 |
| Babiker, ZOE; Hogan, C; Ustianowski, A; Wilkins, E | 1 |
| Alloui, C; Bouhassoune, K; Calboreanu, A; Dény, P; Gordien, E; Legal, F; Podevin, P; Rico-Garcia, M; Salmon-Céron, D; Sogni, P | 1 |
2 review(s) available for tenofovir and Amazon Black Fever
| Article | Year |
|---|---|
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
1 trial(s) available for tenofovir and Amazon Black Fever
| Article | Year |
|---|---|
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Recurrence; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2019 |
15 other study(ies) available for tenofovir and Amazon Black Fever
| Article | Year |
|---|---|
Bulevirtide and tenofovir combination therapy for hepatitis D virus infection: longer treatment and more diverse trial populations are needed.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Humans; Tenofovir; Treatment Outcome | 2023 |
Pembrolizumab-induced acute exacerbation of hepatitis D.
Topics: Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; RNA; Tenofovir | 2023 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
Topics: Antiviral Agents; Brazil; Coinfection; Disease Transmission, Infectious; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferons; Male; Models, Theoretical; Tenofovir; Viral Load | 2018 |
Should alanine aminotransferase flares mean stopping antiviral therapy in patients with cirrhosis?
Topics: Alanine Transaminase; Antiviral Agents; Hepatitis D; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2019 |
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Topics: Aged; Antiviral Agents; Coinfection; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Lipopeptides; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Patient Acuity; RNA, Viral; Tenofovir; Treatment Outcome | 2019 |
Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis.
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Tenofovir; Virus Replication | 2019 |
First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy.
Topics: Adenine; Adult; Coinfection; Hepatitis B; Hepatitis D; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
Topics: Adult; Coinfection; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Male; Tenofovir; Viral Load | 2016 |
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir; Viral Load; Virus Replication | 2017 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Cirrhosis; Nucleotides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?
Topics: Acute Disease; Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis D; Hepatitis Delta Virus; Humans; Interferons; Lamivudine; Male; Organophosphonates; RNA, Viral; Superinfection; Tenofovir; Young Adult | 2012 |
Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
Topics: Adenine; Alanine Transaminase; Amino Acid Sequence; Anti-HIV Agents; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis D; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; RNA, Viral; Superinfection; Tenofovir; Time Factors; Viral Load | 2006 |